Theravance Biopharma Inc
TBPH | NASDAQ
$17.05
+$0.03 (+0.18%)
At close: Sep 21, 2026, 4:00 PM ET
$17.05
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
+0.18%
(1D)Rating
Updated: Aug 20, 2026Key Statistics
Market Data
Market Cap $883.67M
1D Range
17.04 17.07
52W Range
13.08 21.03
Valuation (TTM)
PE 16.88
PB 3.05
EV/EBITDA 8.78
Valuation (NTM)
Forward PE 9.20
Forward PEG -0.45
Price Target $17
Cash Flow
FCF Yield 5.9%
SBC Adj. FCF Yield 3.6%
SBC Impact -37.7%
Margins
Gross Margin 89.4%
Operating Margin -2.9%
FCF Margin 49.7%
Growth (CAGR)
Revenue 3Y | 5Y 26.7% |
10.2%
Dil EPS 3Y | 5Y -55.3% |
-30.8%
FCF 3Y | 5Y 32.1% |
2539.8%
Returns
ROA 11.4%
ROE 19.4%
ROIC 0.9%
Financial Health
Net Cash
$332.11M
Current Ratio 13.54
Interest Coverage 4.03
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for t...
Sector Healthcare
Industry Biotechnology
Employees 90
IPO Date May 15, 2014
Website www.theravance.com
Fiscal Year January - December
Latest News
8 months ago · zacks.com
Is the Options Market Predicting a Spike in Theravance Biopharma Stock?Investors need to pay close attention to TBPH stock based on the movements in the options market lately.
8 months ago · zacks.com
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-TermWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
8 months ago · zacks.com
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-TermWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Analyst Summary
# of Analysts
6
Consensus
Hold
Price Target
$17
Downside
-0.29%
Buy (0)
Hold (6)
Sell (0)
Add to Watchlist
Select watchlists to add or remove TBPH